First Tracks Biotherapeutics (TRAX) — Working Capital to Net Assets Ratio
First Tracks Biotherapeutics (TRAX) has a Working Capital to Net Assets ratio of 97.9% as of June 2026. Working capital of $165.30 Million (current assets of $177.75 Million minus current liabilities of $12.45 Million) is measured against net assets of $168.80 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
First Tracks Biotherapeutics Working Capital to Net Assets (2023–2025)
This chart shows how First Tracks Biotherapeutics's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2023 to 2025. As of June 2026, the ratio stands at 97.9%, reflecting working capital of $165.30 Million against net assets of $168.80 Million USD. Explore TRAX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Annual Working Capital to Net Assets for First Tracks Biotherapeutics (2023–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for First Tracks Biotherapeutics from 2023 to 2025, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see TRAX asset base.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 99.3% | $285.38 Million | $287.49 Million | $316.40 Million | $31.02 Million | ▲ +8.9 pp |
| 2024 | 90.3% | $353.75 Million | $391.60 Million | $389.93 Million | $36.18 Million | ▼ -2.5 pp |
| 2023 | 92.8% | $380.33 Million | $409.85 Million | $398.56 Million | $18.22 Million | — |